

## Scientific Organizer

Prof. Dr. Nisar P. Malek  
 Medizinische Hochschule Hannover  
 Klinik für Gastroenterologie,  
 Hepatologie und Endokrinologie und  
 Institut für Molekularbiologie  
 Carl-Neuberg-Str. 1, 30625 Hannover, Germany  
 Fon: +49 (0)511 532-4585  
 Fax: +49 (0)511 532-4283  
 Email: Malek.Nisar@MH-Hannover.de

## Congress Office

AIO in der Deutschen Krebsgesellschaft e.V.  
 Straße des 17. Juni 106 – 108, 10623 Berlin, Germany  
 Fon: +49 (0)30 322932-933  
 Fax: +49 (0)30 322932-943  
 Email: geschaeftsstelle@aio-portal.de  
 Internet: www.aio-portal.de


## Authorized Congress Agency

EMC Event & Meeting Company GmbH  
 MCI - Munich Office, Ms. Julia Brod  
 Neumarkter Str. 21, 81673 Munich, Germany  
 Fon: +49 (0)89 549096-74  
 Fax: +49 (0)89 549096-75  
 Email: brod@emc-event.com

## Certification:

The event is accredited as follows:  
 AIO – 6 Points / Landesärztekammer Berlin – 8 CME Points

Hotel Pullman Berlin Schweizerhof  
 Budapester Straße 25  
 10787 Berlin  
 Germany



In Cooperation with:

**AIO**  
**dkfz.**

**FMP**

**MHH**

Hannover Medical School

**TRAIN**

Translationalallianz in Niedersachsen

## Attention:

A participation fee will not be charged. Travel expenses will not be reimbursed. A separate invitation/registration is necessary to participate in the „8. AIO-Herbstkongress“.

For further information please visit:  
[www.aio-portal.de](http://www.aio-portal.de)

**ACADEMIC DRUG DEVELOPMENT IN ONCOLOGY  
 - TRANSLATING BASIC SCIENCE RESEARCH  
 INTO INNOVATIVE TREATMENTS**

**16<sup>th</sup> NOVEMBER 2011 IN BERLIN**



**AIO**

Abstract Deadline: 21<sup>st</sup> October 2011

Please send your Abstract as a word file (.doc or .docx) to [brod@emc-event.com](mailto:brod@emc-event.com)

Dear Colleagues,

We would like to take the opportunity to cordially invite you to attend the 3<sup>rd</sup> AIO-Symposium „Academic Drug Development in Oncology - Translating Basic Science Research Into Innovative Treatments“ on 16<sup>th</sup> November 2011 in Berlin.

The meeting will be held at Pullman-Hotel Schweizerhof in the run-up of the 8<sup>th</sup> AIO Autumn Congress which will take place from 17<sup>th</sup> to 20<sup>th</sup> November at the same venue.

The AIO (Working Group for Medical Oncology of the German Cancer Society) will arrange the meeting in cooperation with the their study group „Wirkstoffentwicklung / Frühe Phase I/II-Studien“, together with „Deutsches Krebsforschungszentrum (DKFZ)“, „Forschungsinstitut für Molekulare Pharmakologie (FMP)“, „Medizinische Hochschule Hannover (MHH)“ and „Translational-Allianz in Niedersachsen (TRAIN)“.

Following the concept of the previous symposia we invited a number of renowned scientists who will present projects that aim at developing new therapies against cancer. For this symposium we decided to focus on three subjects. First we will discuss very recent developments in the field of mitosis research. Mitosis already constitutes one of the most important targets for anti-cancer drugs. However, based on the vast progress that has been made in the last few years on the molecular regulators of cell division new and more specific drugs will emerge and potentially revolutionize the way we treat tumors in the future.

The myc oncogene is one of the most important, if not the most important protein in the development of a wide variety of malignancies. For many years myc was seen as a potentially highly variable but undruggable target. We invited several experts in the field of myc research to discuss the question whether myc and the molecular pathways it regulates must still be seen as undruggable or if new possibilities of targeting this key component of oncogenesis will enter clinical medicine in the future.

Many of the new compounds that have been derived from academic or industrial research enter the clinical testing phase too slowly or do not live up to the expectations clinicians and patients have in later stage trials. Innovative phase 1 studies which help to unravel the potential and the risks of a new drug early on and might also guide the selection of the “right” patient to the “right” drug are highly needed. The third session of our symposium will therefore aim to show new strategies in phase 1 trial design thereby facilitating successful transition from laboratory to clinical drug research.

In addition we cordially invite everyone to submit abstracts on all aspects of academic drug development in oncology ranging from innovative targets, assay development and screening technology to new substances with activity in pre-clinical models or early clinical trials. We will choose several speakers from the abstract submissions who will get an opportunity to present their work as short talks. The remaining abstracts will be presented during the poster session.

We look forward to welcoming you on the occasion of the symposium on 16<sup>th</sup> November 2011 in Berlin.

With best regards

Prof. Dr. Nisar Malek

For the AIO Arbeitsgruppe “Wirkstoffentwicklung / Frühe Phase I/II-Studien“

## PROGRAM

09.00	<b>Welcome</b> U. Graeven, AIO
<b>Session 1</b>	
	<b>Mitosis as a Target</b> Chair: I. Hoffmann, Heidelberg
09.10 - 09.35	<b>Chemical biology of cytokinesis</b> U. Eggert, London
09.45 - 10.10	<b>Targeting mitotic processes with small-molecule inhibitors</b> A. Musacchio, Dortmund
10.20 - 10.50	<b>Coffee Break</b>
10.50 - 11.15	<b>Plk1-related phosphoproteomics approaches to study cell division</b> A. Santamaria, Basel
11.25 - 11.50	<b>Chemical synthesis of new apoptosis-inducing agents addressing the colchicine binding site of Tubulin</b> H.-G. Schmalz, Köln
12.00 - 13.30	<b>Lunch and Poster Session</b>
<b>Session 2</b>	
	<b>Myc as a Target</b> Chair: H. Oschkinat, Berlin
13.30 - 13.55	<b>Small-molecule inhibitors of transcription factors</b> T. Berg, Leipzig
14.05 - 14.30	<b>From strategies and small molecules to target Myc for cancer therapy</b> M. Eilers, Würzburg
14.40 - 15.05	<b>Regulation of gene transcription by the MYC/MAX/MAD network</b> B. Lüscher, Aachen
15.15 - 15.25	<b>Short Talk 1</b>
15.30 - 15.40	<b>Short Talk 2</b>
15.45 - 16.15	<b>Coffee Break</b>
<b>Session 3</b>	
	<b>Innovative Concepts for Phase I / II Studies</b> Chair: S. Hegewisch-Becker, Hamburg
16.15 - 16.40	<b>Expectations of the Pharma Industry for Phase I &amp; II Trials</b> J. Stieglmaier, Nürnberg
16.50 - 17.15	<b>Incorporation of biomarker development in early clinical trials – the right way forward?</b> T. Arkenau, London
17.25 - 17.50	<b>Phase I study design for molecular targeted drugs – need for a change?</b> J. Drevs, Köln
18.00	<b>Concluding remarks</b> N. Malek

## CHAIRS & SPEAKERS

Dr. Hendrik-Tobias Arkenau  
LOC Leaders in Oncology Care, London

Prof. Dr. Thorsten Berg  
Universität Leipzig, Institut für Organische Chemie

Prof. Dr. Joachim Drevs  
Tumorzentrum UniSantus, Köln

Prof. Dr. Ulrike Eggert  
King's College, London

Prof. Dr. Martin Eilers  
Universität Würzburg, Theodor-Boveri-Institut

PD Dr. Ullrich Graeven  
Kliniken Maria Hilf, Mönchengladbach

Prof. Dr. Susanna Hegewisch-Becker  
Internistische Praxisgemeinschaft Eppendorf, Hamburg

PD Dr. Ingrid Hoffmann  
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg

Prof. Dr. Bernhard Lüscher  
Universitätsklinikum Aachen,  
Institut für Biochemie und Molekularbiologie

Prof. Dr. Nisar Malek  
Medizinische Hochschule Hannover

Prof. Dr. Andrea Musacchio  
Max-Planck-Institut für molekulare Physiologie, Dortmund

Prof. Dr. Hartmut Oschkinat,  
Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin

Dr. Anna Santamaria  
Universität Basel, Biozentrum

Prof. Dr. Hans-Günther Schmalz  
Universität Köln, Institut für Organische Chemie

Dr. Julia Stieglmaier  
Novartis Pharma GmbH, Business Unit Oncology, Nürnberg